Stevanato Group S.P.A. - Q1 2023 Financial Summary
Business Context and Reporting Period
This Form 6-K filing presents the interim condensed consolidated financial statements for Stevanato Group S.P.A. for the three months ended March 31, 2023. The Company is a global provider of drug containment, drug delivery, and diagnostic solutions, operating primarily through two segments: Biopharmaceutical and Diagnostic Solutions and Engineering. The reporting period reflects continued organic growth driven by high-value solutions, offset by the normalization of COVID-19 related demand and significant capital expenditures for capacity expansion.
Key Financial Metrics
| Metric (EUR Million) | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | 238.0 | 212.1 | +12.2% |
| Gross Profit | 76.3 | 67.5 | +13.0% |
| Gross Margin | 32.0% | 31.8% | +0.2 pp |
| Operating Profit | 40.6 | 37.9 | +7.1% |
| Operating Margin | 17.1% | 17.9% | -0.8 pp |
| Net Profit | 28.3 | 27.8 | +1.8% |
| Diluted EPS (EUR) | 0.11 | 0.10 | +10.0% |
| EBITDA | 59.0 | 53.1 | +11.1% |
| Adjusted EBITDA | 61.9 | 54.0 | +14.7% |
| Free Cash Flow | (91.0) | (48.8) | -86.5% |
| Cash & Equivalents | 158.8 | 228.7 | -30.6% |
| Net Debt | (46.5) | 46.0 | Shift to Net Debt |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased 12.2% (11.2% at constant currency). The Biopharmaceutical segment grew 13.4%, driven by a 24.7% increase in high-value solutions. The Engineering segment grew 7.1% externally, with a significant 110.3% increase in inter-segment revenue due to equipment sales for capacity expansion.
- Profitability: While Gross Profit margin improved to 32.0%, Operating Profit margin declined to 17.1% from 17.9%. This compression was primarily due to increased Selling, General, and Administrative (SG&A) expenses related to public company structuring and new hires, as well as higher R&D costs.
- Finance Costs: Net finance expenses increased significantly to EUR 4.6 million (from EUR 1.6 million) due to a net foreign exchange loss of EUR 4.3 million, driven by the strengthening of the Mexican Peso against the Euro and USD.
- Capital Expenditures: CAPEX surged to EUR 113.2 million (from EUR 53.8 million), reflecting heavy investment in new facilities in the U.S. (Fishers, Indiana), Italy (Latina and Piombino Dese), and China to expand capacity for high-value products.
- Cash Flow: Operating cash flow improved to EUR 37.1 million, but Free Cash Flow turned significantly negative at EUR (91.0) million due to the massive increase in capital investments.
Guidance, Outlook, and Risks
- COVID-19 Impact: Management expects COVID-19 related revenue to decrease in 2023, estimated at 2-3% of total revenue (down from ~11% in 2022).
- Capacity Expansion: The Company is prioritizing investments in the U.S. and Italy. The Fishers, Indiana facility is on track for commercial operations in early 2024. The Latina, Italy facility is expected to begin commercial production in Q4 2023.
- Backlog: Backlog stood at approximately EUR 954.8 million as of March 31, 2023, slightly down from EUR 957.0 million at year-end 2022. New order intake for Q1 2023 was EUR 235.7 million, down from EUR 324.3 million in Q1 2022, reflecting the normalization of COVID orders.
- Risks: Key risks include the potential for further supply chain disruptions, volatility in energy prices (natural gas and electricity) due to the Russia-Ukraine conflict, and foreign exchange fluctuations. The Company notes that gas prices have stabilized in Q1 2023 but remain a monitoring priority.
- Financing: In early 2023, the Company secured two new loans totaling EUR 130.0 million to support ongoing capital investments.
Investor Verification Checklist
- High-Value Mix: Verify the sustainability of the 24.7% growth in high-value solutions and its impact on long-term margin expansion.
- FX Exposure: Assess the impact of the Mexican Peso strengthening on future earnings and the effectiveness of hedging strategies.
- CAPEX Execution: Monitor the timeline and cost overruns for the new facilities in Fishers (USA) and Latina (Italy) to ensure they meet the projected commercial launch dates.
- Working Capital: Review the increase in Days Sales Outstanding (DSO) from 68 to 82 days and the rise in inventory levels to ensure efficient capital management.
- Non-Recurring Items: Note the EUR 2.9 million in start-up costs for new plants included in Q1 2023 results and their exclusion from Adjusted EBITDA.